AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
sulfadiazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-infectives, sulfonamides | 2500 | 68-35-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.13 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 57 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 684.95 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 100 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.29 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.55 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.44 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 7 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.344 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.374 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 8.260 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.799 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 64.960 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 77.050 | % | High | 1 |
| herg | hERG pIC50 | 3.765 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.824 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.170 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 53.390 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK12,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 52 | |||
| kinase-selectivity-class | AXL,CDK9,ERBB2,GRK2,MAPK7,SIK2,STK33,TEK | 8 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.521 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 1.879 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 83.780 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.352 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 81.220 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 0.783 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 94.150 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 42.180 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1011.579 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 11, 1941 | FDA | LEDERLE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Lipase increased | 216.86 | 30.60 | 50 | 1946 | 11061 | 90615390 |
| Drug hypersensitivity | 186.48 | 30.60 | 119 | 1877 | 463490 | 90162961 |
| Pancreatitis | 129.73 | 30.60 | 51 | 1945 | 69775 | 90556676 |
| Drug reaction with eosinophilia and systemic symptoms | 92.77 | 30.60 | 35 | 1961 | 42723 | 90583728 |
| Cerebral toxoplasmosis | 77.84 | 30.60 | 15 | 1981 | 1390 | 90625061 |
| Pancytopenia | 68.87 | 30.60 | 39 | 1957 | 120224 | 90506227 |
| Bone marrow failure | 57.84 | 30.60 | 23 | 1973 | 32198 | 90594253 |
| Pneumonia aspiration | 49.29 | 30.60 | 22 | 1974 | 40918 | 90585533 |
| Coma | 45.47 | 30.60 | 25 | 1971 | 72607 | 90553844 |
| Hepatocellular injury | 42.84 | 30.60 | 18 | 1978 | 28940 | 90597511 |
| Astigmatism | 42.05 | 30.60 | 9 | 1987 | 1405 | 90625046 |
| Toxoplasmosis | 34.58 | 30.60 | 8 | 1988 | 1777 | 90624674 |
| Deafness transitory | 33.51 | 30.60 | 8 | 1988 | 2035 | 90624416 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neuritis | 261.76 | 43.77 | 69 | 3914 | 6151 | 42611201 |
| Pulmonary vasculitis | 261.26 | 43.77 | 69 | 3914 | 6197 | 42611155 |
| Neurological symptom | 229.41 | 43.77 | 69 | 3914 | 9922 | 42607430 |
| Eosinophilic granulomatosis with polyangiitis | 212.80 | 43.77 | 63 | 3920 | 8575 | 42608777 |
| Respiratory symptom | 209.64 | 43.77 | 66 | 3917 | 11040 | 42606312 |
| Pulmonary alveolar haemorrhage | 206.60 | 43.77 | 70 | 3913 | 14746 | 42602606 |
| Total lung capacity abnormal | 204.78 | 43.77 | 53 | 3930 | 4390 | 42612962 |
| Antineutrophil cytoplasmic antibody positive | 195.99 | 43.77 | 51 | 3932 | 4314 | 42613038 |
| Forced expiratory volume decreased | 185.09 | 43.77 | 55 | 3928 | 7575 | 42609777 |
| Vasculitis | 177.01 | 43.77 | 66 | 3917 | 18328 | 42599024 |
| Sleep disorder due to a general medical condition | 172.98 | 43.77 | 64 | 3919 | 17389 | 42599963 |
| Obstructive airways disorder | 171.57 | 43.77 | 70 | 3913 | 24689 | 42592663 |
| Pulmonary fibrosis | 166.51 | 43.77 | 70 | 3913 | 26611 | 42590741 |
| Mite allergy | 160.85 | 43.77 | 45 | 3938 | 5001 | 42612351 |
| Dust allergy | 158.39 | 43.77 | 45 | 3938 | 5287 | 42612065 |
| Mycotic allergy | 157.65 | 43.77 | 44 | 3939 | 4847 | 42612505 |
| Conjunctivitis allergic | 153.81 | 43.77 | 45 | 3938 | 5866 | 42611486 |
| Spirometry abnormal | 150.92 | 43.77 | 43 | 3940 | 5103 | 42612249 |
| Full blood count abnormal | 146.05 | 43.77 | 66 | 3917 | 29810 | 42587542 |
| Hypothyroidism | 144.66 | 43.77 | 67 | 3916 | 32017 | 42585335 |
| Lung disorder | 135.83 | 43.77 | 73 | 3910 | 47850 | 42569502 |
| Normochromic normocytic anaemia | 135.02 | 43.77 | 45 | 3938 | 8986 | 42608366 |
| Haemoptysis | 129.92 | 43.77 | 70 | 3913 | 46097 | 42571255 |
| Nodule | 120.60 | 43.77 | 45 | 3938 | 12489 | 42604863 |
| Asthma | 112.92 | 43.77 | 71 | 3912 | 62243 | 42555109 |
| Loss of personal independence in daily activities | 111.48 | 43.77 | 65 | 3918 | 49751 | 42567601 |
| Wheezing | 110.91 | 43.77 | 67 | 3916 | 54714 | 42562638 |
| Therapeutic product effect incomplete | 104.51 | 43.77 | 71 | 3912 | 70868 | 42546484 |
| Arteriosclerosis coronary artery | 103.22 | 43.77 | 45 | 3938 | 18632 | 42598720 |
| Arteriosclerosis | 101.56 | 43.77 | 44 | 3939 | 17945 | 42599407 |
| Capillaritis | 94.99 | 43.77 | 25 | 3958 | 2203 | 42615149 |
| Productive cough | 69.71 | 43.77 | 49 | 3934 | 51518 | 42565834 |
| Anxiety | 66.87 | 43.77 | 68 | 3915 | 118492 | 42498860 |
| Hypoxia | 60.66 | 43.77 | 51 | 3932 | 69735 | 42547617 |
| Condition aggravated | 60.64 | 43.77 | 96 | 3887 | 260658 | 42356694 |
| Toxic epidermal necrolysis | 60.00 | 43.77 | 35 | 3948 | 26715 | 42590637 |
| Pain in extremity | 55.15 | 43.77 | 69 | 3914 | 150535 | 42466817 |
| Thrombosis | 45.47 | 43.77 | 43 | 3940 | 68468 | 42548884 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pulmonary vasculitis | 304.83 | 30.54 | 70 | 5568 | 6490 | 110577171 |
| Neuritis | 296.45 | 30.54 | 70 | 5568 | 7329 | 110576332 |
| Neurological symptom | 262.68 | 30.54 | 74 | 5564 | 15534 | 110568127 |
| Eosinophilic granulomatosis with polyangiitis | 241.94 | 30.54 | 64 | 5574 | 10622 | 110573039 |
| Total lung capacity abnormal | 240.41 | 30.54 | 54 | 5584 | 4529 | 110579132 |
| Respiratory symptom | 234.09 | 30.54 | 67 | 5571 | 14878 | 110568783 |
| Pulmonary alveolar haemorrhage | 231.20 | 30.54 | 71 | 5567 | 20079 | 110563582 |
| Antineutrophil cytoplasmic antibody positive | 224.25 | 30.54 | 52 | 5586 | 5024 | 110578637 |
| Forced expiratory volume decreased | 192.65 | 30.54 | 56 | 5582 | 13120 | 110570541 |
| Mite allergy | 186.62 | 30.54 | 46 | 5592 | 5757 | 110577904 |
| Dust allergy | 185.09 | 30.54 | 46 | 5592 | 5955 | 110577706 |
| Mycotic allergy | 180.43 | 30.54 | 45 | 5593 | 5909 | 110577752 |
| Spirometry abnormal | 178.93 | 30.54 | 44 | 5594 | 5453 | 110578208 |
| Conjunctivitis allergic | 178.51 | 30.54 | 46 | 5592 | 6885 | 110576776 |
| Vasculitis | 176.47 | 30.54 | 67 | 5571 | 35806 | 110547855 |
| Obstructive airways disorder | 173.68 | 30.54 | 71 | 5567 | 46078 | 110537583 |
| Normochromic normocytic anaemia | 153.94 | 30.54 | 47 | 5591 | 13010 | 110570651 |
| Haemoptysis | 150.00 | 30.54 | 73 | 5565 | 71281 | 110512380 |
| Full blood count abnormal | 147.59 | 30.54 | 67 | 5571 | 55985 | 110527676 |
| Sleep disorder due to a general medical condition | 145.83 | 30.54 | 65 | 5573 | 52047 | 110531614 |
| Hypothyroidism | 136.67 | 30.54 | 69 | 5569 | 72830 | 110510831 |
| Arteriosclerosis coronary artery | 123.80 | 30.54 | 47 | 5591 | 25071 | 110558590 |
| Arteriosclerosis | 120.83 | 30.54 | 46 | 5592 | 24721 | 110558940 |
| Pulmonary fibrosis | 120.15 | 30.54 | 71 | 5567 | 101971 | 110481690 |
| Nodule | 111.88 | 30.54 | 47 | 5591 | 32584 | 110551077 |
| Capillaritis | 107.77 | 30.54 | 25 | 5613 | 2414 | 110581247 |
| Cerebral toxoplasmosis | 106.55 | 30.54 | 26 | 5612 | 3116 | 110580545 |
| Lung disorder | 92.11 | 30.54 | 75 | 5563 | 179972 | 110403689 |
| Loss of personal independence in daily activities | 84.19 | 30.54 | 66 | 5572 | 149954 | 110433707 |
| Therapeutic product effect incomplete | 74.24 | 30.54 | 73 | 5565 | 223732 | 110359929 |
| Drug reaction with eosinophilia and systemic symptoms | 73.46 | 30.54 | 48 | 5590 | 82047 | 110501614 |
| Hypoxia | 66.28 | 30.54 | 54 | 5584 | 129461 | 110454200 |
| Asthma | 65.66 | 30.54 | 72 | 5566 | 250219 | 110333442 |
| Productive cough | 65.64 | 30.54 | 51 | 5587 | 114254 | 110469407 |
| Toxic epidermal necrolysis | 57.77 | 30.54 | 36 | 5602 | 56691 | 110526970 |
| Wheezing | 57.73 | 30.54 | 68 | 5570 | 255162 | 110328499 |
| Pancytopenia | 56.17 | 30.54 | 61 | 5577 | 209552 | 110374109 |
| Thrombosis | 52.85 | 30.54 | 44 | 5594 | 108618 | 110475043 |
| Condition aggravated | 46.42 | 30.54 | 110 | 5528 | 734726 | 109848935 |
| Anxiety | 45.91 | 30.54 | 71 | 5567 | 345007 | 110238654 |
| Pulmonary embolism | 34.06 | 30.54 | 48 | 5590 | 214426 | 110369235 |
| Astigmatism | 32.83 | 30.54 | 9 | 5629 | 1700 | 110581961 |
| Pain in extremity | 31.85 | 30.54 | 74 | 5564 | 487044 | 110096617 |
| Deafness transitory | 31.80 | 30.54 | 8 | 5630 | 1085 | 110582576 |
| Bone marrow failure | 31.43 | 30.54 | 25 | 5613 | 57823 | 110525838 |
| Pulmonary venous thrombosis | 30.75 | 30.54 | 6 | 5632 | 252 | 110583409 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01EC02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Intermediate-acting sulfonamides |
| ATC | J01EE02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives |
| ATC | J01EE06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE SULFONAMIDES AND TRIMETHOPRIM Combinations of sulfonamides and trimethoprim, incl. derivatives |
| FDA CS | M0020790 | Sulfonamides |
| FDA EPC | N0000175503 | Sulfonamide Antibacterial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D003049 | Coccidiostats |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35442 | antiparasitic agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:35818 | coccidiostat |
| CHEBI has role | CHEBI:35820 | antiprotozoal drug |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:50502 | EC 2.5.1.15 (dihydropteroate synthase) inhibitor |
| CHEBI has role | CHEBI:74234 | EC 1.1.1.153 [sepiapterin reductase (<small>L</small>-<i>erythro</i>-7,8-dihydrobiopterin forming)] inhibitor |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
| CHEBI has role | CHEBI:88188 | drug allergen |
Related Drugs by ATC class:
J01EC Intermediate-acting sulfonamides 2 drugs
J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chorioretinitis | indication | 46627006 | DOID:8886 |
| Skin ulcer | indication | 46742003 | |
| Ulcerative colitis | indication | 64766004 | DOID:8577 |
| Congenital toxoplasmosis | indication | 73893000 | DOID:13336 |
| Toxoplasmosis | indication | 187192000 | DOID:9965 |
| Toxoplasmosis associated with acquired immunodeficiency syndrome | indication | 421666009 | |
| Rheumatic Fever Prevention | indication | ||
| Burn Wound Infections | indication | ||
| Encephalitis due to Toxoplasmosis | indication | ||
| Minor Bacterial Skin Infections | indication | ||
| Collagenous colitis | off-label use | 19311003 | DOID:0060183 |
| Psoriasis with arthropathy | off-label use | 33339001 | |
| Crohn's disease | off-label use | 34000006 | |
| Rheumatoid arthritis | off-label use | 69896004 | DOID:7148 |
| Systemic sclerosis | off-label use | 89155008 | DOID:418 |
| Juvenile rheumatoid arthritis | off-label use | 410795001 | |
| Toxoplasmosis Prevention | off-label use | ||
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Third trimester pregnancy | contraindication | 41587001 | |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Megaloblastic anemia due to folate deficiency | contraindication | 85649008 | DOID:14026 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Superimposed infection | contraindication | 193198003 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Aplastic anemia | contraindication | 306058006 | DOID:12449 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Porphyria | contraindication | 418470004 | |
| Slow acetylator due to N-acetyltransferase enzyme variant | contraindication | 425079005 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Systemic antibacterial action against sensitive organisms to surgery | Indication |
| Dogs | Systemic antibacterial action against sensitive organisms to debridement | Indication |
| Dogs | Control of bacterial infection during the treatment of acute urinary tract infections | Indication |
| Dogs | Control of bacterial infection during the treatment of acute bacterial complications of distemper | Indication |
| Dogs | Control of bacterial infection during the treatment of acute respiratory tract infections | Indication |
| Dogs | Control of bacterial infection during the treatment of acute alimentary tract infections | Indication |
| Dogs | Control of bacterial infection during the treatment of wound infections | Indication |
| Dogs | Control of bacterial infection during the treatment of abscesses | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during treatment of acute strangles | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during respiratory infections | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during acute urogenital infections | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during wound infections | Indication |
| Horses | Systemic antibacterial action against sensitive organisms during abscesses | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Tribrissen 120 Tablets, Tribrissen 30 Tablets, Tribrissen 480 Tablets, Tribrissen 960 Tablets | Intervet Inc. | 2 |
| Tribrissen 24% Injection | Intervet Inc. | 2 |
| Tribrissen 48% Injection | Intervet Inc. | 2 |
| Di-Trim Tablets | Zoetis Inc. | 2 |
| Tribrissen 400 Oral Paste | Intervet Inc. | 2 |
| Di-Trim 24% | Zoetis Inc. | 2 |
| Di-Trim 48% Injection | Zoetis Inc. | 2 |
| Di-Trim 400 Paste | Zoetis Inc. | 2 |
| Tribrissen 60 Oral Suspension | Intervet Inc. | 2 |
| ReBalance | Pegasus Laboratories Inc. | 2 |
| EQUISUL-SDT | Aurora Pharmaceutical Inc. | 2 |
| Uniprim Powder | Neogen Corp. | 2 |
| Tucoprim Powder | Zoetis Inc. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.6 | acidic |
| pKa2 | 2.03 | Basic |
| pKa3 | 1.41 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2B | GPCR | IC50 | 4.96 | WOMBAT-PK | |||||
| Dihydrofolate reductase | Enzyme | IC50 | 6.89 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | IC50 | 6.03 | WOMBAT-PK | |||||
| Aurora kinase A | Kinase | IC50 | 4.68 | CHEMBL | |||||
| High affinity choline transporter 1 | Transporter | IC50 | 4.24 | WOMBAT-PK | |||||
| Dihydropteroate synthase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| D00587 | KEGG_DRUG |
| 547-32-0 | SECONDARY_CAS_RN |
| 4017497 | VANDF |
| C0038675 | UMLSCUI |
| CHEBI:9328 | CHEBI |
| CHEMBL439 | ChEMBL_ID |
| CHEMBL1200351 | ChEMBL_ID |
| DB00359 | DRUGBANK_ID |
| D013411 | MESH_DESCRIPTOR_UI |
| 5215 | PUBCHEM_CID |
| 12635 | IUPHAR_LIGAND_ID |
| 421 | INN_ID |
| 0N7609K889 | UNII |
| 10171 | RXNORM |
| 13920 | MMSL |
| 2022 | MMSL |
| 5523 | MMSL |
| 7798 | MMSL |
| 87818 | MMSL |
| d00118 | MMSL |
| 002814 | NDDF |
| 014626 | NDDF |
| 371400009 | SNOMEDCT_US |
| 74523009 | SNOMEDCT_US |
| 768490003 | SNOMEDCT_US |
| 422 | INN_ID |
| 0N7609K889 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| SULFADIAZINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42806-757 | TABLET | 500 mg | ORAL | ANDA | 19 sections |
| sulfADIAZINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-842 | TABLET | 500 mg | ORAL | ANDA | 10 sections |